The National Health Surveillance Agency (Anvisa) approved, this Friday (19), exceptional and temporary measures that will allow speeding up the authorization of the use of medicines and vaccines for the prevention and treatment of monkey pox – or monkeypox.
The decision of the Collegiate Board takes place at an extraordinary meeting of the agency held on the morning of this Friday. The rule, of an exceptional and temporary nature, allows the Ministry of Health to request the agency to waive registration of drugs and vaccines that have already been approved for the prevention or treatment of monkeypox by international authorities specified in the respective resolution.
“It is important to make it clear that Anvisa is exercising its role as a regulatory agency. The waiver of registration is a regulatory act. And this act does not signify the tacit approval of what is to come. Faced with yet another challenge, we are using a tool that is part of the full exercise of our role”, said CEO Antonio Barra Torres.
So far, according to the Ministry of Health, Brazil has recorded 3,450 confirmed cases of monkeypox.
The disease was recorded in the states of São Paulo (2,279), Rio de Janeiro (403), Minas Gerais (159), Federal District (141), Paraná (83), Goiás (136), Bahia (29), Ceará (29). ), Rio Grande do Norte (14), Espírito Santo (8), Pernambuco (19), Tocantins (1), Maranhão (2), Alagoas (1), Acre (1), Amazonas (15), Pará (4) , Paraíba (1), Piauí (2), Rio Grande do Sul (54), Mato Grosso (13), Mato Grosso do Sul (12), and Santa Catarina (44).
In update
Source: CNN Brasil
